Aldehyde Oxidase

An aldehyde oxidoreductase expressed predominantly in the LIVER; LUNGS; and KIDNEY. It catalyzes the oxidation of a variety of organic aldehydes and N-heterocyclic compounds to CARBOXYLIC ACIDS, and also oxidizes quinoline and pyridine derivatives. The enzyme utilizes molybdenum cofactor and FAD as cofactors.

Also Known As:

Networked: 18 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Terao, Mineko: 2 articles (08/2011 - 02/2005)
2.	Garattini, Enrico: 2 articles (08/2011 - 02/2005)
3.	Kitamura, Shigeyuki: 1 article (02/2015)
4.	Sanoh, Seigo: 1 article (02/2015)
5.	Sugihara, Kazumi: 1 article (02/2015)
6.	Ohta, Shigeru: 1 article (02/2015)
7.	Tayama, Yoshitaka: 1 article (02/2015)
8.	Zhou, Shi-Sheng: 1 article (02/2010)
9.	Sun, Wu-Ping: 1 article (02/2010)
10.	Li, Da: 1 article (02/2010)

Related Diseases

1.	Lung Injury 12/01/1990 - "This study evaluated the effect of ischemia-reperfusion (I-R) on pulmonary capillary permeability in isolated rabbit lungs and the roles of xanthine oxidase (XO), aldehyde oxidase (AO), and neutrophils (PMN) in producing this lung injury. "
2.	Ischemia 12/01/1990 - "This study evaluated the effect of ischemia-reperfusion (I-R) on pulmonary capillary permeability in isolated rabbit lungs and the roles of xanthine oxidase (XO), aldehyde oxidase (AO), and neutrophils (PMN) in producing this lung injury. "
3.	Neoplasms (Cancer) 08/01/2011 - "We highlight the potential offered by human aldehyde oxidase targeting for the development of new pharmacological agents, limiting our attention to the realms of antiobesity and anti-cancer drugs. " 05/15/1994 - "Aldehyde oxidase activity was found in normal liver tissue but not in other normal or tumor tissues. " 07/01/1987 - "Because TBM is capable of overcoming at least one of the modalities of MTX resistance, defective polyglutamylation, and may be more efficiently detoxified than MTX by the action of hepatic aldehyde oxidase, it has the potential to be a useful agent for the treatment of MTX-resistant tumors." 03/01/1980 - "Fourteen phosphorylated acetals and aldehydes were synthesized for testing in vitro as inhibitors or substrates of aldehyde oxidase, an enzyme involved in the conversion of aldophosphamide to inactive carboxyphosphamide, and for concurrent in vivo administration with cyclophosphamide to mice bearing L1210 ascites tumor cells. "
4.	Nervous System Diseases (Neurological Disorders) 11/20/2002 - "Molybdenum cofactor deficiency is a fatal neurological disorder, which follows an autosomal-recessive trait and is characterized by combined deficiency of the enzyme, sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase. " 01/01/2000 - "Molybdenum cofactor deficiency (MoCoD) is an autosomal recessive, fatal neurological disorder, characterized by the combined deficiency of sulphite oxidase, xanthine dehydrogenase and aldehyde oxidase. "
5.	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 07/07/1997 - "Aldehyde oxidase (AO), a protein involved in the catabolism of catecholamines, is the product of a gene potentially responsible for one of the familial forms of the motor neuron disease, amyotrophic lateral sclerosis (ALS). " 03/01/1995 - "Analysis of aldehyde oxidase and xanthine dehydrogenase/oxidase as possible candidate genes for autosomal recessive familial amyotrophic lateral sclerosis."

Related Drugs and Biologics

1.	Xanthine Oxidase
2.	Xanthine Dehydrogenase
3.	Sulfite Oxidase
4.	Cytochrome P-450 Enzyme System (Cytochrome P450)
5.	Molybdenum cofactor deficiency
6.	Xanthine
7.	Glutamic Acid (Glutamate)
8.	Uridine Diphosphate (UDP)
9.	Tetrachlorodibenzodioxin (TCDD)
10.	Staphylococcal Protein A (A, Protein)